Feeds:
Posts
Comments

Posts Tagged ‘Januvia’

COMING UP SOON: BDI’s Social Communications and Healthcare half-day gathering. NYC, May 11 – all details here. I will be leading a roundtable. Use discount code IMPACT for $155 registration rate.

*****

TODAY’S NEWS

Allergan – Rolling high-stakes legal dice re: Botox. Here and here.

Novo’s Victoza: nice results in comparison with Merck‘s Januvia. Plus, an experimental Januvia competitor gets dropped by Forest Labs.

Experimental once-a-day malaria drug looking really good – An experimental once-a-day malaria drug worked as well at treating the mosquito-borne illness as Novartis AG’s twice-daily pill Coartem, according to a study published today in the journal Lancetmore

RECOMMENDED

Account Management Training – Need to make your account managers more effective? Creative and successful programs are available from Impactiviti’s partner network.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Surround Yourself with Smart People.

JUST FOR FUN

Serene Sunrises. 40. A visual treat.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

Where to get your overview of Social Media in Pharma? Right here: http://bit.ly/socialrx

TODAY’S NEWS

Pharma’s new hot properties vaccines.

Boehringer Ingelheim pressing forward with its experimental DPP-4 inhibitor for diabetes – Boehringer Ingelheim Pharmaceuticals, Inc. today announced the conclusion of the linagliptin pivotal Phase III clinical trials, including more than 4,000 patients in 40 countries worldwide. Phase II data for linagliptin were presented earlier this year at the annual American Diabetes Association (ADA) Scientific Sessions. Full results from the Phase III trials will be presented at international scientific congresses in 2010 and beyond...more

Merck’s diabetes drug Januvia significantly lowers blood sugar – A post-hoc analysis, presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD), of data pooled from studies of 104 weeks in duration showed ‘Januvia®’ (sitagliptin), when taken alone or in combination with metformin, provided significant blood sugar lowering over two yearsmore

RECOMMENDED

Product/Launch training. The Impactiviti Partner Network has great providers to help you develop your new product training – print, on-line, and live. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Has the game changed in a dramatic way in pharma social media? I think it may be likely – my initial thoughts on Google’s Sidewiki tool, which allows user commentary on ANY site.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

Now Available – Archived interview on Social Media in Pharma last Friday with Paul Chaney – feel free to forward the link (http://bit.ly/29kAoN) to your colleagues.

TODAY’S NEWS

Abbott wins the bidding for Solvay’s drug unit Abbott Laboratories will announce today the €5bn ($7.3bn) acquisition of Solvay’s pharmaceutical company, bringing a five-month takeover battle to an end and highlighting continued consolidation in the industry. The US drugmaker beat UCB of Belgium and Nycomed of Switzerland to buy the division, which is valued at between €4.5bn and €5bnmore

The Medicines Company gets encouraging results from Angiomax study – The Medicines Company today announced the presentation of 2-year clinical results from the landmark HORIZONS-AMI Trial. The trial showed that patients who had suffered the most severe form of heart attack were significantly less likely to suffer cardiac death and had better overall survival if treated with Angiomax® (bivalirudin) while undergoing angioplasty compared with those treated with heparin plus a platelet glycoprotein IIb/IIIa inhibitor (GPI) during angioplasty...more

Merck‘s diabetes drug Januvia with pancreatitis link? Merck says no, but FDA concerned.

RECOMMENDED

Social Media Strategy. We do that. If your company is wrestling with how to move forward with social media, contact us (stevew at impactiviti dot com, or phone at 973-947-7429) to talk.

PLUS

Is the Apple iPhone 3GS good enough to record the video of an entire conference presentation? Well, yes, it kinda can. Here are the results of my little experiment, from last week’s PharmaMed conference.

Coming up next month:

DigitalPharma

Oct. 19-21 – eXL’s Digital Pharma conference, Bridgewater, NJ. This event will be quite progressive, with more of an informal “unconference” format to maximize interaction. I’ll be co-leading a pre-conference workshop on the 19th on social media, and live-blogging/Twittering. Here’s a discount code for 15% your registration: P615WOO

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

BREAKING RUMORPfizer in talks to acquire Wyeth.

Will contract sales reps rule in the future? Revenues are now following a “cyclical pattern surrounding patent expirations,” In Vivo quotes Ryan as saying. So pharma companies need to have sales forces that can follow the same kind of cycle, shrinking as revenues sink, she suggests.

Merck’s Januvia + metformin for diabetes, 2 years in – looking good. Merck & Co’s diabetes drug Januvia substantially improves blood sugar levels over two years of treatment when combined with the older drug metformin and is generally well tolerated, new data on Tuesday showed.

Hmmm…will names of BI reps who signed onto a class action suit become known to their bosses?

—––

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Impactiviti is a pharma consultancy focused on helping pharma/biotech/medical devices companies identify optimal vendors for training/marketing needs.

Reblog this post [with Zemanta]

Read Full Post »

King begins hostile takeover proceedings with Alpharma – Brain Markison, King’s ceo, is disappointed that Dean Mitchell, Alpharma’s ceo, hasn’t responded to his initial offer $1.4 billion offer, which amounted to $33 a share. So Markison raised the bid to $37, or $1.6 billion, and is going directly to shareholders…more

J&J’s Christine Poon to retire.

ImClone to BMS: maybe we’re already dating – The drugmaker calls the $60-a-share bid by Bristol-Myers Squibb ‘inadequate,’ and goes on to say in a statement this morning that famed corporate raider Carl Icahn, who chairs ImClone’s board, has had ’several conversations with the ceo of a large pharmaceutical company,’ which was not named…more And more BMS-to-ImClone here, and on the response here.

Meanwhile, BMS grounding its fleet – Bristol-Myers Squibb is preparing to shut down its aviation operation at Trenton-Mercer Airport, sell four aircraft and dismiss about 32 employees as the drugmaker and leading Mercer County employer seeks to cut costs, according to sources familiar with the company’s plans…more

Amgen violating patents?

Can Botox relieve migraines?

FDA reports rare brain infection/death with Rituxan – The agency says a woman died of the rare viral infection more than a year and a half after discontinuing the drug, which is used to treat rheumatoid arthritis and non-Hodgkin’s lymphoma, and is marketed in the US by Genentech and Biogen Idec…more

Sanofi fills top job with Viehbacher from Glaxo – Chris Viehbacher, GlaxoSmithKline Plc’s head of North American operations, is to take a top job with French drugmaker Sanofi-Aventis, a person familiar with the situation said on Tuesday…more

Januvia, 2 years in: thumbs up – Merck & Co’s diabetes drug Januvia substantially improves blood sugar levels over two years of treatment when combined with the older drug metformin and is generally well tolerated, new data on Tuesday showed…more

Experimental diabetes drug (BMS/AZ) promising – Bristol-Myers Squibb and AstraZeneca’s experimental diabetes drug Onglyza significantly improves blood sugar control when added to older medicines, researchers said on Monday…more

Fast track for cancer drug Afinitor – An experimental drug from Swiss drugmaker Novartis AG has been granted priority review in the United States as a treatment for advanced kidney cancer. Novartis said on Tuesday that RAD001 or everolimus, which it plans to sell under the brand name Afinitor, had been accepted for fast review given the medicine’s potential to help patients who fail to respond to standard therapy…more

Tysabri for cancer? – Biogen Idec and Elan Corp have launched the first clinical trial of their multiple sclerosis drug Tysabri for patients with relapsed or refractory multiple myeloma, the companies said on Friday…more

Celgene gets a fast track for lung cancer drugCelgene Corporation (NASDAQ: CELG) today announced that Amrubicin has been granted Fast Track product designation by the U.S. Food and Drug Administration (FDA) for the treatment of small cell lung cancer after first-line chemotherapy…more

Is Pfizer interested in Bayer?

Sample trouble: drives up costs? – Free drug samples provided by drugmakers to doctors could actually be costing uninsured patients more in the long run, according to a new retrospective study in the Southern Medical Journalmore

The Allergan-Medicis “death match” – Allergan and Medicis have been locked in a highly profitable death-match for several years, with both companies bringing out me-too versions of the others’ products, just like Coke and Pepsi…more

But will it be posted in the Post Office? The FDA 20The first list is a bare-bones compilation naming 20 medications and the potential issue for each. It provides no indication of how widespread or serious the problems might be, leading some consumer advocates to question its usefulness, and prompting industry worries that skittish patients might stop taking a useful medication if they see it listed…more

Zimmer growing some spine.

GSK and Valeant on epilepsy drug tie-up.

Pfizer and Medivation to work together on Alzheimer’s/Huntington’s treatment.

Genentech and Roche acting merged: facilities closing – The fallout from Roche’s looming acquisition of Genentech has started. Roche will close a research facility in Palo Alto, Calif., where a 1,000 people work, the San Jose Mercury News reports. Back in July Roche said it would pull the plug on the lab in Stanford Research Park, but the company hedged, saying the closure would happen if the bid for Genentech were successful. Genentech has demurred so far, but most people think it’s just a matter of time before the deal happens. And now, Roche told the Mercury News it’s closing the plant, no matter what…more

No vigil for Provigil at TakedaCephalon Inc. will end its co- promotion agreement with Takeda Pharmaceutical Co. in North America for the sleep-disorder drug Provigil, because net sales dropped to less than $850 million this year…more

UCB: Yep, we’re specialty now. Translation: downsizing – If you can’t buy a biopharmaceutical company, you might as well become one. UCB Pharma last week announced that it will trim 17 percent of its work force—about 2,000 employees—in order to reestablish the company as specialty drug firm….more

Every once in a while you want to visit here – Forbes’ New Drugs to Watch page.

This is way cool – A little-used cancer drug called bryostatin can repair brain tissue if it’s administered within 24 hours after a stroke, according to U.S. researchers. Current stroke treatments must be administered within three hours and aren’t able to repair damaged brain tissue, the scientists said…more

Shire and Vyvanse for ADHD – One of the recent unheralded successes of the drug world was Shire Pharmaceuticals‘ launch of Vyvanse, a new, long-acting treatment for attention deficit and hyperactivity disorder. The fact that so little attention has been paid to Vyvanse is a shame because the take-up of this drug has been impressive — it appears to be well on its way to supplanting Adderall XR as the king of the ADHD drugs…more

I kinda think this one’s a no-win for Genentech – Negative public opinion just keeps piling on to Genentech regarding its pricing policy on Lucentis and Avastin. This weekend saw a big Associated Press story describe how the company is refusing to ask the FDA to approve Avastin for use in treating “wet age-related macular degeneration,” an eye condition that leads to blindness. Genentech is doing this, most people believe, because Avastin would be a much cheaper treatment for wet AMD than Lucentis, another Genentech drug. It costs about $60 per dose to use Avastin on the disease, and $2,000 to use Lucentis…more

Speaking of no-win – releasing Vytorin data…more

Reblog this post [with Zemanta]

Read Full Post »

The Good Stuff:

BMS gets approval for new oncology drug (for breast cancer) Ixempra.

Merck gets new HIV drug (Isentress) approved in the U.S. And, their Januvia diabetes drug gets new uses approved.

Abraxis gets cancer drugs approved.

J&J gets Doribax (for intra-abdominal and urinary tract infections) approved.

Bayer reports upbeat MS drug results.

Glaxo: new use of HIV drug Lexiva OK’d.

The Bummers:

Say what? Viagra and other impotence drugs may be causing hearing loss??

Pfizer pulls the plug on Exubera, lets partner Nektar know after the press release.

Novartis details job cuts, and some executive shuffling at the top. They will end a contract sales force agreement with InVentiv Health as part of the pullback.

Major job cuts at struggling Boston Scientific.

J&J‘s drug biz not growing as rapidly as has been typical. Here’s why.

Genentech posts “only” 22% year over year earnings growth. This is apparently considered a disappointment…

VA scraps most use of Avandia.

Byetta and acute pancreatitis: beware!

Pfizer and Wyeth report large charges in their earnings reports (buy Lilly has good numbers)

Speculation, gossip, other stuff:

Biogen hangs out a “For Sale” sign.

Pfizer jumps into Sermo, the physician networking site. Not everyone is thrilled.

Who is Pfizer going to buy up next? Genzyme? Everyone is hot on biotech acquisitions these days…

Read Full Post »